Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have received a consensus recommendation of "Hold" from the twelve research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $61.90.

A number of equities analysts have commented on HALO shares. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. HC Wainwright reissued a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a research note on Tuesday, May 13th. Leerink Partnrs cut Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, Morgan Stanley lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $73.00 to $62.00 in a research report on Wednesday, May 14th.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now directly owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. The trade was a 12.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,697 shares of company stock valued at $1,276,552 in the last ninety days. Corporate insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock worth $634,999,000 after purchasing an additional 386,618 shares in the last quarter. Snyder Capital Management L P lifted its holdings in Halozyme Therapeutics by 2.6% in the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock worth $199,294,000 after purchasing an additional 105,086 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Halozyme Therapeutics by 4.8% in the 1st quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company's stock worth $205,156,000 after purchasing an additional 146,677 shares in the last quarter. Congress Asset Management Co. lifted its holdings in Halozyme Therapeutics by 8.8% in the 1st quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company's stock worth $136,088,000 after purchasing an additional 172,971 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Halozyme Therapeutics by 4.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company's stock worth $129,478,000 after purchasing an additional 95,600 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

HALO stock traded up $0.79 during mid-day trading on Friday, reaching $54.54. 1,200,951 shares of the company traded hands, compared to its average volume of 1,617,623. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The company has a market capitalization of $6.72 billion, a P/E ratio of 15.90, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics has a 52-week low of $42.01 and a 52-week high of $70.51. The company has a fifty day moving average price of $59.88 and a 200-day moving average price of $55.86.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company's revenue for the quarter was up 35.2% on a year-over-year basis. During the same quarter last year, the company posted $0.79 EPS. As a group, analysts anticipate that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.